200 related articles for article (PubMed ID: 16875616)
1. [Basic Consensus on endocrinotherapy for breast cancer].
Jiang ZF; Xu BH; Song ST
Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):238-9. PubMed ID: 16875616
[No Abstract] [Full Text] [Related]
2. [Estrogen and progesterone receptors in breast cancer].
Sonoo H
Nihon Rinsho; 2000 Apr; 58 Suppl():146-53. PubMed ID: 11025988
[No Abstract] [Full Text] [Related]
3. Tamoxifen for early breast cancer.
Nurs Times; 2001 Jun 21-27; 97(25):41. PubMed ID: 11957988
[No Abstract] [Full Text] [Related]
4. Cross-trial comparison of different AIs.
Vakaet L
Breast J; 2009; 15(5):544; author reply 545. PubMed ID: 19601953
[No Abstract] [Full Text] [Related]
5. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
6. [Pharmaceutical therapy of breast cancer].
Láng I; Kahán Z; Pintér T; Dank M; Boér K; Pajkos G; Faluhelyi Z; Pikó B; Eckhardt S; Horváth Z
Magy Onkol; 2010 Sep; 54(3):237-54. PubMed ID: 20870601
[No Abstract] [Full Text] [Related]
7. Progesterone receptor testing: not the right time to be buried.
Colozza M; Larsimont D; Piccart MJ
J Clin Oncol; 2005 Jun; 23(16):3867-8; author reply 3869-70. PubMed ID: 15923594
[No Abstract] [Full Text] [Related]
8. [Factors predicting failure of adjuvant hormonotherapy of breast carcinoma. A study in tamoxifen treated patients].
Petráková K; Nenutil R; Grell P; Fabian P; Zichová I; Svoboda M; Palácová M; Vyzula R
Klin Onkol; 2008; 21(5):303-8. PubMed ID: 19202962
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
10. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
11. Cyclin D-1, interleukin-6, HER-2/neu, transforming growth factor receptor-II and prediction of relapse in women with early stage, hormone receptor-positive breast cancer treated with tamoxifen.
Muss HB; Bunn JY; Crocker A; Plaut K; Koh J; Heintz N; Rincon M; Weaver DL; Tam D; Beatty B; Kaufman P; Donovan M; Verbel D; Weiss L
Breast J; 2007; 13(4):337-45. PubMed ID: 17593037
[TBL] [Abstract][Full Text] [Related]
12. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
13. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen in early breast cancer.
Bryce CJ
Lancet; 1998 Aug; 352(9125):403. PubMed ID: 9717952
[No Abstract] [Full Text] [Related]
15. Lumpectomy and tamoxifen alone without additional radiotherapy for women 70 years of age or older with estrogen receptor-positive breast cancer.
Ferretti G; Mandalà M; Bria E; Carlini P; Papaldo P; Fabi A; Felici A; Cognetti F
Breast Cancer Res Treat; 2005 Apr; 90(3):319. PubMed ID: 15830147
[No Abstract] [Full Text] [Related]
16. Evaluation of estrogen dependency of human breast cancers. II. Clinical evaluation of tamoxifen in advanced primary and recurrent breast cancer.
Nishiki M; Yamane M; Amano K; Yasuda K; Okumichi T; Ezaki H
Hiroshima J Med Sci; 1984 Jun; 33(2):163-6. PubMed ID: 6480380
[No Abstract] [Full Text] [Related]
17. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance.
van Agthoven T; Sieuwerts AM; Meijer-van Gelder ME; Look MP; Smid M; Veldscholte J; Sleijfer S; Foekens JA; Dorssers LC
J Clin Oncol; 2009 Feb; 27(4):542-9. PubMed ID: 19075277
[TBL] [Abstract][Full Text] [Related]
18. Evolution of knowledge related to breast cancer heterogeneity: a 25-year retrospective.
Fisher B; Redmond CK; Fisher ER
J Clin Oncol; 2008 May; 26(13):2068-71. PubMed ID: 18445835
[No Abstract] [Full Text] [Related]
19. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen in early breast cancer.
Benson JR
Lancet; 1998 Aug; 352(9125):404-5. PubMed ID: 9717955
[No Abstract] [Full Text] [Related]
[Next] [New Search]
